Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEW FRONTIER HEALTH CORPORATION

(NFH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment -
Trading -
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth -
EBITDA / Sales
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
-
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the companyĺs current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
-
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m -
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions -
Divergence of Target Price -
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 77% by 2023.
Weaknesses
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector Other Healthcare Facilities & Services
1st jan.Capitalisation (M$)Investor Rating
NEW FRONTIER HEALTH CORPORA..29.30%1 466
-
CVS HEALTH CORPORATION20.64%108 485
HCA HEALTHCARE, INC.22.44%66 581
REDE D'OR SÃO LUIZ S.A.-1.99%25 756
LABORATORY CORPORATION OF A..27.83%25 405
FRESENIUS MEDICAL CARE AG &..2.84%24 355
QUEST DIAGNOSTICS INCORPORA..6.99%16 656
DR. SULAIMAN AL HABIB MEDIC..49.72%15 232
OAK STREET HEALTH, INC.-8.36%13 496
DAVITA INC.3.60%12 917
PING AN HEALTHCARE AND TECH..-7.07%12 909
UNIVERSAL HEALTH SERVICES, ..6.70%12 503
ENCOMPASS HEALTH CORPORATIO..-3.63%7 933
CHEMED CORPORATION-11.70%7 501
TENET HEALTHCARE CORPORATIO..65.11%7 041
JINXIN FERTILITY GROUP LIMI..16.46%5 943
More Results